Table 3.
Primary and secondary outcomes.
| Cryoprecipitate Group (n = 109) |
Fibrinogen Group (n = 97) |
Total (n = 206) |
p-Value | |
|---|---|---|---|---|
| MTE | 16 (14.7) | 14 (14.4) | 30 (14.6) | 1.000 |
| Portal and hepatic vein thrombosis | 14 (12.8) | 13 (13.4) | 27 (13.1) | 1.000 |
| Hepatic artery thrombosis | 2 (1.8) | 0 (0) | 2 (1.0) | 0.529 |
| Ischemic stroke | 0 (0) | 1 (1.0) | 1 (0.5) | 0.953 |
| 30-day MACE | 24 (22.0) | 13 (13.4) | 37 (18.0) | 0.154 |
| 1-year mortality | 10 (9.2) | 7 (7.2) | 17 (8.3) | 0.798 |
| 1-year graft failure | 16 (14.7) | 8 (8.3) | 24 (11.7) | 0.223 |
Note: values are presented as number (%). Abbreviations: MTE, major thromboembolic event; MACE, major adverse cardiovascular event.